By Disabled People for Disabled People

Let's focus on what we can do, not what we can't!

Online Platform By Disabled People for Disabled People

Let's focus on what we can do, not what we can't!

Online Platform By Disabled People for Disabled People

  • Home
  • >
  • Latest Headlines
  • >
  • UK Expands Referral Criteria for Zolgensma to Heavier Children – SMA News Today

UK Expands Referral Criteria for Zolgensma to Heavier Children – SMA News Today

Saturday, 5 February, 2022

UK Expands Referral Criteria for Zolgensma to Heavier Children – SMA News Today

Image source: smauk.org.uk

 
The U.K. has expanded the referral criteria for the approved gene therapy Zolgensma to include children with spinal muscular atrophy (SMA) who weigh up to 18 kilograms (40 lbs), according to a press release from SMA UK.
The expansion to a higher weight category — 15 to 18 kgs (33 to 40 lbs) — was advanced by the National Multidisciplinary Team (NMDT) which, along with infusion centers in England, provide services for children in England and Wales. The NMDT brings together infusion center representatives and others to ensure joint and equitable decision-making about the delivery of medicines such as Zolgensma.
Initially, the NMDT invited referrals for children, 12 months or younger, who had never been treated (treatment naïve) or were untreated. This included those 6 months and younger who were pre-symptomatic, or newly diagnosed and untreated. Children 7 to 12 months who were newly diagnosed and untreated were also eligible for referrals.
Read more at: https://smanewstoday.com/news-posts/2022/02/02/uk-expands-zolgensma-referral-criteria-heavier-children/

Categories :
  • Latest Headlines
  • Spinal muscular atrophy
Socials :

Recent posts

Ability Today to your inbox.

By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.

Ability Today to your inbox.

By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.

Our Awards and Partners

Copyright © 2022 All rights reserved